Abeona Therapeutics (ABEO) Stock Price, News & Analysis

Abeona Therapeutics logo
$2.60 +0.18 (+7.44%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$2.61 +0.01 (+0.38%)
As of 11/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Abeona Therapeutics Stock (NASDAQ:ABEO)

Advanced

Key Stats

Today's Range
$2.36
▼
$2.62
50-Day Range
$2.29
▼
$5.85
52-Week Range
$2.09
▼
$7.65
Volume
2.54 million shs
Average Volume
2.02 million shs
Market Capitalization
$148.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00
Consensus Rating
Moderate Buy

Company Overview

Abeona Therapeutics, Inc. is a biotechnology company focused on developing cell and gene therapies for serious and rare diseases. Its work includes treatments designed to address the underlying genetic causes of disease.

The company’s lead product, ZEVASKYN (prademagene zamikeracel), is an autologous gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, a rare inherited skin disorder. Made from a patient’s skin cells, the therapy uses genetic modification to help cells produce type VII collagen and is applied to wounds. The U.S. Food and Drug Administration approved ZEVASKYN in 2025.

Abeona has also pursued investigational gene therapies for other rare genetic conditions. Its development programs have included treatments for inherited lysosomal storage disorders, though investigational therapies are not approved for general use.

AI Generated. May Contain Errors.

Abeona Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
64th Percentile Overall Score

ABEO MarketRank™: 
3.218858362225 of 5 stars

Abeona Therapeutics scored higher than 64% of companies evaluated by MarketBeat, and ranked 185th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Abeona Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Abeona Therapeutics has a consensus price target of $21.00, representing about 707.7% upside from its current price of $2.60.

  • Amount of Analyst Coverage

    Abeona Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Abeona Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Abeona Therapeutics are expected to grow in the coming year, from ($0.97) to ($0.48) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Abeona Therapeutics is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Abeona Therapeutics is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Abeona Therapeutics has a P/B Ratio of 1.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    31.77% of the float of Abeona Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Abeona Therapeutics has a short interest ratio ("days to cover") of 21.67, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Abeona Therapeutics has recently decreased by 1.95%, indicating that investor sentiment is improving.
  • Dividend Yield

    Abeona Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Abeona Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Abeona Therapeutics has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 17 news articles for Abeona Therapeutics this week, compared to 5 articles on an average week.
  • MarketBeat Follows

    1 people have added Abeona Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Abeona Therapeutics insiders have sold 763.20% more of their company's stock than they have bought. Specifically, they have bought $34,350.00 in company stock and sold $296,508.00 in company stock.

  • Percentage Held by Insiders

    7.10% of the stock of Abeona Therapeutics is held by insiders.

  • Percentage Held by Institutions

    80.56% of the stock of Abeona Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Abeona Therapeutics' insider trading history.
Receive ABEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABEO Stock News Headlines

Abeona Therapeutics (NASDAQ:ABEO) Stock Bumped Up to Hold by Wall Street Zen
Your Copy is on Hold (Claim it now)
James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on Elon Musk's next big industry play. He estimates it could create 1.8 million new millionaires in the coming years, and shows how to position in the company at its center for under $60. Inside: the company's name and ticker, plus an FCC filing James believes reveals Elon's plan to take over a $25 trillion industry. He also flags December 8 as a key date.tc pixel
Abeona Therapeutics (ABEO) Q3 2026 Earnings Call Transcript
See More Headlines

ABEO Stock Analysis - Frequently Asked Questions

Abeona Therapeutics' stock was trading at $5.27 on January 1st, 2026. Since then, ABEO stock has decreased by 50.7% and is now trading at $2.60.

Abeona Therapeutics Inc. (NASDAQ:ABEO) announced its quarterly earnings results on Monday, November, 9th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.09. The biopharmaceutical company had revenue of $13.49 million for the quarter, compared to the consensus estimate of $14.82 million. Abeona Therapeutics had a negative net margin of 160.30% and a negative trailing twelve-month return on equity of 44.82%.
Read the conference call transcript
.

Abeona Therapeutics shares reverse split on the morning of Tuesday, July 5th 2022.The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Abeona Therapeutics' top institutional shareholders include AIGH Capital Management LLC (5.07%), Goldman Sachs Group Inc. (2.03%), State Street Corp (1.84%) and Nan Fung Trinity HK Ltd. (0.97%). Insiders that own company stock include Vishwas Seshadri, Joseph Walter Vazzano, Brendan M O'malley, Madhav Vasanthavada, Faith L Charles, Leila Alland, Christine Berni Silverstein, Mark Alvino and Eric Crombez.
View institutional ownership trends
.

Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Abeona Therapeutics investors own include Alibaba Group (BABA), Tesla (TSLA), Advanced Micro Devices (AMD), Bristol Myers Squibb (BMY), NIO (NIO), Micron Technology (MU) and NVIDIA (NVDA).

Company Calendar

Last Earnings
11/09/2026
Today
11/16/2026
Jefferies Global Healthcare Conference
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ABEO
Previous Symbol
OTCMKTS:ACCP
CIK
318306
Employees
226
Year Founded
2013

Price Target and Rating

High Price Target
$30.00
Low Price Target
$17.00
Potential Upside/Downside
+707.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.07)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$71.18 million
Net Margins
-160.30%
Pretax Margin
-160.80%
Return on Equity
-44.82%
Return on Assets
-32.51%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.69
Quick Ratio
6.40

Sales & Book Value

Annual Sales
$5.82 million
Price / Sales
25.53
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.20 per share
Price / Book
1.18

Miscellaneous

Outstanding Shares
57,150,000
Free Float
53,090,000
Market Cap
$148.59 million
Optionable
Optionable
Beta
1.50

Social Links

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:ABEO) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners